SCHEMBL894211

SCHEMBL894211

CC1(C)OB(CCCCBr)OC1(C)C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4190077 0.98
SCHEMBL12055744 0.93
SCHEMBL23969676 0.85 ANPEP (0.31)
SCHEMBL31509639 0.82
SCHEMBL15928015 0.76 LPL (0.42)
SCHEMBL20139091 0.76 LPL (0.42)
SCHEMBL15923410 0.76 LPL (0.42)
SCHEMBL8394655 0.76
SCHEMBL18387576 0.75 LPL (0.37)
SCHEMBL15927940 0.71

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11389464-B2 Arginase inhibitors as therapeutics MARS, INCORPORATED (US) 2022-07-19 US disclosed
EP-3719024-A1 ARGINASE INHIBITORS AS THERAPEUTICS Mars, Incorporated (US) 2020-10-07 EP disclosed
US-20200246362-A1 Arginase Inhibitors as Therapeutics MARS, INCORPORATED 2020-08-06 US disclosed
US-20200223871-A1 Arginase Inhibitors and Methods of Use ASTRAZENECA AB (SE) 2020-07-16 US disclosed
US-20200223871-A1 Arginase Inhibitors and Methods of Use ASTRAZENECA AB (SE) 2020-07-16 US disclosed
CN-106008569-B9 Borate as arginase inhibitor and composition and application thereof 马尔斯公司 2020-05-22 CN disclosed
EP-3034509-B1 ARGINASE INHIBITORS AS THERAPEUTICS MARS INC (US) 2020-04-22 EP disclosed
CN-106008569-B Borate as arginase inhibitor and composition and application thereof 马尔斯公司 2020-04-03 CN disclosed
US-10603330-B2 Arginase inhibitors as therapeutics MARS, INCORPORATED (US) 2020-03-31 US disclosed
EP-3240777-B1 ARGINASE INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS ONCOARENDI THERAPEUTICS SA (PL) 2019-07-24 EP disclosed
US-20120083469-A1 INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS MARS, INCORPORATED 2012-04-05 US disclosed
US-20120083469-A1 INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS MARS, INCORPORATED 2012-04-05 US disclosed
US-20120083469-A1 INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS MARS, INCORPORATED 2012-04-05 US disclosed
EP-2389352-A2 ARGINASE INHIBITORS AND METHODS OF USE The Trustees Of The University Of Pennsylvania (US) 2011-11-30 EP disclosed
WO-2011133653-A1 INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS MARS, INCORPORATED (US) 2011-10-27 WO disclosed
WO-2011133653-A1 INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS MARS, INCORPORATED (US) 2011-10-27 WO disclosed
US-8040818-B2 Method for exchange of upkeep-relevant information with a computer-supported, upkeep system ENDRESS + HAUSER PROCESS SOLUTIONS AG (CH) 2011-10-18 US disclosed
US-20100189644-A1 ARGINASE INHIBITORS AND METHODS OF USE THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2010-07-29 US disclosed
US-20100189644-A1 ARGINASE INHIBITORS AND METHODS OF USE THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2010-07-29 US disclosed
WO-2010085797-A2 ARGINASE INHIBITORS AND METHODS OF USE THE TRUSTEES OF UNIVERSITY OF PENNSYLVANIA (US) 2010-07-29 WO disclosed